Assessment of tobacco product pharmacology and behavior in humans.
Ended Awarded Last action
- Contract number
- HHSF22301002T
- Awardee
-
Lovelace Biomedical And Environmental Research Institute, Inc. UEI N1UBCLRAPNG6 Part of Lovelace Biomedical Research Institute
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $1,403,705
Award facts
- Contract value 100% obligated
- $1,403,705.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541720 Research and Development in the Social Sciences and Humanities
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Albuquerque, NM 87108, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $140,993 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $30,609 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,232,103 |
About this award
This federal contract award, valued at $1,403,705.20, was issued by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute. The contract is a delivery order issued under the Tobacco Products Pharmacology Study master indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle.
The contract does not have a set-aside designation. LBERI, a non-profit contract research organization, will provide preclinical research services to support the development of treatments and cures for respiratory diseases. This includes conducting studies on topics such as HIV therapeutics, pain disorders, COVID-19 medical countermeasures, infectious disease modeling, and opioid addiction treatments. LBERI has extensive expertise in areas like inhalation toxicology, animal modeling, and translational science, which it leverages to support federal agencies like the National Institutes of Health (NIH), Biomedical Advanced Research and Development Authority (BARDA), and Leidos.
Quick answers
Who was awarded contract HHSF22301002T?
HHSF22301002T was awarded to Lovelace Biomedical And Environmental Research Institute, Inc. by Food and Drug Administration (Department of Health and Human Services) on August 17, 2016.
How much is contract HHSF22301002T worth?
The government has obligated $1,403,705 on HHSF22301002T.
Is contract HHSF22301002T an order under another contract?
Yes. HHSF22301002T is a delivery order under HHSF223201310033I, an indefinite delivery contract, on Tobacco Products Pharmacology Study.
Was contract HHSF22301002T competed?
The extent of competition for HHSF22301002T was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award